J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Multiple Organ Dysfunction Syndrome in Bone Marrow Transplantation
William D. Haire,Elizabeth I. Ruby,Bruce Geoffrey Gordon,Kashinath D. Patil,L. C. Stephens,G. D. Kotulak,Elizabeth C. Reed,Julie M. Vose,Philip J. Bierman,Anne Kessinger,James O. Armitage +10 more
TL;DR: Single organ dysfunction during BMT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations.
Journal ArticleDOI
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Julie M. Vose,Brian K. Link,Michael L. Grossbard,Myron S. Czuczman,Antonio J. Grillo-Lopez,Richard I. Fisher +5 more
TL;DR: The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
Journal Article
High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging.
TL;DR: Patients with relapsed lymphoma and bone marrow metastases who receive high dose therapy followed by peripheral stem cell transplantation can experience long-term event-free survival.
Journal ArticleDOI
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
Andrew D. Zelenetz,Leo I. Gordon,William G. Wierda,Jeremy S. Abramson,Ranjana H. Advani,C. Babis Andreadis,Nancy L. Bartlett,John C. Byrd,Myron S. Czuczman,Luis Fayad,Richard I. Fisher,Martha Glenn,Thomas M. Habermann,Nancy L. Harris,Richard T. Hoppe,Steven M. Horwitz,Chris R. Kelsey,Youn H. Kim,Susan Krivacic,Ann S. LaCasce,Auayporn Nademanee,Pierluigi Porcu,Oliver W. Press,Rachel Rabinovitch,Nishitha Reddy,Erin Reid,Ayman Saad,Lubomir Sokol,Lode J. Swinnen,Christina Tsien,Julie M. Vose,Lynn D. Wilson,Joachim Yahalom,Nadeem Zafar,Mary A. Dwyer,Hema Sundar +35 more
TL;DR: This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
Journal ArticleDOI
Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.
Nabin Khanal,R. Gregory Bociek,Baojiang Chen,Julie M. Vose,James O. Armitage,Philip J. Bierman,Lori J. Maness,Matthew A. Lunning,Krishna Gundabolu,Vijaya Raj Bhatt +9 more
TL;DR: Within the limits of this retrospective study, cautious use of prophylactic‐dose low‐molecular‐weight heparin (LMWH) may be safe in thrombocytopenic patients with hematologic malignancy‐associated VTE.